Facebook Linkedin Youtube X-twitter Instagram
Professional Syndicates Complex, Sharif Abdel Hamid Sharaf Street, 31, Amman, Jordan
About Jordan
  • Home
  • Membership
    • Membership Request
    • Associate Members
    • Types of memberships
    • General Payment Service via Cliq
  • Activity
    • Lectures and conferences
  • Health Education
  • Scientific materials
  • Gallary
    • Videos
    • Photos
  • About US
  • Contact us
  • English
Login
  • Home
  • Membership
    • Membership Request
    • Associate Members
    • Types of memberships
    • General Payment Service via Cliq
  • Activity
    • Lectures and conferences
  • Health Education
  • Scientific materials
  • Gallary
    • Videos
    • Photos
  • About US
  • Contact us
  • English
  • من نحن
    • تاريخ الجمعية
    • هيكل الجمعية
    • ادارة الجمعية
    • تطوع معنا
  • العضوية
    • طلب انتساب
    • الاعضاء المنتسبون
    • Types of memberships in the Society of Cardiologists
  • Home
  • نشاطات
  • مواد علمية
  • Health Education
  • جاليري
    • فيديو
    • صور
  • اتصل بنا
Uncategorized
jordan heart August 20, 2025 0

2025 ACC/AHA Hypertension Guideline — GP Practical Summary

2025 ACC/AHA Hypertension Guideline — GP Practical Summary
Source & Date: American Heart Association / American College of Cardiology Hypertension Guideline (May–Aug 2025).
Published in: JACC, Circulation, Hypertension (DOI: 10.1016/j.jacc.2025.05.007).
1. BP Classification (Office)
1. Normal: <120/<80 mmHg
2. Elevated: 120–129/<80 mmHg
3. Stage 1 HTN: 130–139/80–89 mmHg
4. Stage 2 HTN: ≥140/≥90 mmHg
• Always classify into the higher category if SBP/DBP differ.
• Confirm with ≥2 readings per visit on ≥2 occasions.
2. Accurate BP Measurement
5. Use validated devices (validatebp.org); correct cuff size.
6. Avoid caffeine, exercise, smoking 30 min before.
7. Average ≥2 readings per visit; repeat at ≥2 visits.
8. Re-train staff every 6–12 months.
3. Out-of-Office Monitoring
9. ABPM/HBPM recommended for diagnosis, titration, white-coat & masked HTN.
10. Thresholds:
• HBPM ≥130/80
• Daytime ABPM ≥130/80
• Night ABPM ≥110/65
• 24h ABPM ≥125/75
4. When to Start Medications
11. High risk (CVD, CKD, diabetes, 10y risk ≥7.5%): ≥130/80.
12. Lower risk (<7.5%): ≥140/90; or ≥130/80 after 3–6 months lifestyle.
13. Stage 2 HTN: start 2 first-line drugs, ideally in single-pill combo.
5. Treatment Targets
14. General goal: <130/80 mmHg for most adults.
15. Exceptions: frail elderly, institutionalized, pregnancy (specific targets).
6. Lifestyle Interventions
16. Weight loss: Aim BMI 18.5–24.9; ≥5% loss if overweight.
17. Diet: DASH; Na <2.3 g/day (ideal <1.5 g); ↑ K⁺ if safe.
18. Exercise: ≥150 min/week moderate aerobic + resistance ≥2/week.
19. Alcohol: ≤1 drink/day (women), ≤2 (men).
20. Stress: yoga, meditation, breathing techniques.
7. Special Populations
Stroke / ICH
21. ICH: SBP 150–220 → lower to 130–140 for 7 days; avoid <130 early.
22. Ischemic stroke with thrombolysis: <185/110 before, then <180/105 for 24h.
23. No reperfusion & BP ≥220/120: reduce by ~15% in 24h.
24. Secondary prevention: target <130/80; use thiazide, ACEi, or ARB.
CKD
25. Target <130/80; ACEi/ARB first-line if albuminuria ≥30 mg/g.
26. Avoid ACEi + ARB combo.
Diabetes
27. Target <130/80; ACEi/ARB preferred with albuminuria.
Pregnancy
28. Acute severe HTN (≥160/110): treat within 30–60 min, with gradual reduction over ~30 min. First-line: IV labetalol, oral nifedipine, or methyldopa.
29. Chronic HTN: target <140/90.
30. Safe drugs: labetalol, nifedipine, methyldopa.
• Avoid ACEi, ARB, direct renin inhibitors, mineralocorticoid antagonists, and atenolol (linked to fetal growth restriction & neonatal complications).
OSA
31. Screen in resistant HTN or suggestive symptoms.
32. CPAP + weight loss modestly improve BP.
HIV
33. Standard treatment; monitor drug–drug interactions (esp. with CCBs).
Transplant
34. First-line: amlodipine; avoid verapamil/diltiazem with calcineurin inhibitors.
8. Resistant Hypertension
35. Defined as uncontrolled BP on ≥3 drugs (incl. diuretic) or controlled on ≥4.
36. Add spironolactone if eGFR ≥45; alternatives: amiloride, β-blocker, α-blocker, clonidine.
37. Exclude secondary causes; remove interfering drugs.
38. Renal Denervation (RDN) – Class IIb option if uncontrolled.
9. What’s New in 2025
39. “Hypertensive urgency” renamed “Severe Hypertension” (no organ damage).
40. Primary aldosteronism screening expanded (all resistant HTN).
41. Potassium-based salt substitutes broadly recommended.
42. Avoid lowering SBP <140 in first 24–72h post-reperfusion stroke.
43. Emphasis on community-based screening & team-based care.
10. Hypertensive Emergencies (BP >180/120 + organ damage)
• ICU admission; titratable IV drugs (nicardipine, clevidipine, labetalol, esmolol, hydralazine, enalaprilat).
• Nitrates only for ACS or pulmonary edema.
• If IV unavailable: oral captopril (preferred; rapid under tongue or swallowed).
• Oral nifedipine only in preeclampsia/eclampsia.
• Evidence note: Sublingual captopril reduces SBP & MAP more rapidly than oral in first 30 min, but effect is similar at 60 min.
• Target: reduce ≤25% in 1h, then <160/100 in 2–6h, then 130–140/80–90 in 24–48h.
11. Other Clinical Notes
• Orthostatic Hypotension: Check baseline & after intensification; not a reason to avoid intensive BP control.
• Sexual dysfunction: Diuretics & β-blockers worsen it; ARBs safest. PDE-5 inhibitors safe (not with nitrates).
• Perioperative BP: Continue most drugs; stop ACEi/ARB 24h before major surgery; defer elective surgery if ≥180/110.
12. GP Quick Checklist
☐ Confirm diagnosis with ABPM/HBPM.
☐ Classify & stage BP.
☐ Assess 10y risk (PREVENT tool).
☐ Initiate lifestyle ± drugs per stage/risk.
☐ Use single-pill combos where possible.
☐ Monitor monthly until goal achieved.
☐ Screen for secondary causes if resistant/atypical.
Key Takeaway:
For most adults, target <130/80 mmHg using validated BP methods, lifestyle change, risk-based thresholds for treatment, and single-pill drug combinations.
Special attention: treat pregnancy-related severe hypertension within 30–60 minutes, avoid atenolol, use safe drugs, and apply new terminology (Severe Hypertension).
Resistant hypertension requires structured evaluation and, in select cases, renal denervation.
67 Views
11
Sitting-Rising Test (SRT) and Heart Health – Key PointsAugust 20, 2025
Bridging Communication Gaps in Cardiology: Toward a National Consultation PlatformAugust 20, 2025

مقالات ذات صلة

Uncategorized

PCI Outcomes in Patients with Prior TAVR: Key Findings from a 2025 Study

webadmin May 22, 2025
Uncategorized

Key Trends in Transcatheter Tricuspid Valve Interventions

webadmin April 23, 2025

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

احدث المقالات

  • Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond
  • Management of Hypertension in Primary Care – Key Points
  • You Say NOAC, I Say DOAC: Medicine’s Love of Confusing Jargon
  • New Blood Pressure Guidelines: Key Takeaways
  • Bridging Communication Gaps in Cardiology: Toward a National Consultation Platform

فئات

  • Health Education
  • Previous lectures and conferences
  • Uncategorized

Jordanian Cardiology Society

Jordanian Cardiology Society

Amman-Jordan

00962795001983

Working hours

From Sunday to Thursday

From nine in the morning until four in the afternoon

Important Links

Jordanian Cardiology Society

Research and studies

Medical articles

Login

Privacy Policy

Refund Policy

Cancellation Policy

Delivery Policy

Association Location

Copyright © 2024 Jordanian Cardiologists Association by WebAppRoots. All Rights Reserved.